Group Discussion

Time: 11:20 am
day: Post-Conference Workshop Day


• Which steps in the generation and analysis of microbial and host -omic data are most likely to introduce inconsistencies in data across experiments?
• Which methods for -omics data generation and analysis are more accurate (16s vs. WGS)? What are best practices for Internal QA and benchmarking for -omics based biomarker analyses?
• Given the rapidly evolving state of the field, what types of standardizations across different microbiome therapeutics developers are feasible?
• What public resources are available that could be leveraged for standardization and validation? What resources could the federal government make available to foster these efforts?